From Efficacy Assessment to Pathology, Our Discovery Pharmacology Experts Advance Your Molecule

Our in vitro services deliver solutions that facilitate your decision-making process.

• Primary cell lines (neurons, astrocytes, oligodendrocytes)
• Established cell lines and novel modalities (osteoblasts, HEK, Hela, etc.)
• Models of aging, neurodegeneration, injury, stroke, mitochondrial health and more
• Customized model development
• Metabolic stability/permeability assessment (including drug transporter assessment, permeability)
• Protein binding/tissue binding
• Mass spectrometry (LC-MS/MS) based analysis

Click here for a more comprehensive list of our DMPK services

We offer a wide array of ex vivo services, providing you with the data needed to efficiently make informed decisions.

• Multiplexing offers an extensive list of analytes and can tailor any Luminex® profile to meet your needs
• ELISA analysis
• Fluorescent activated cell sorting (FACS)
• Blood, plasma, serum analysis
  • Pharmacokinetic (PK) modeling
  • Stability
• Targeted tissue analysis (supporting PK/PD modeling)
• Identification of major circulating metabolites
• Gene expression analysis
• Targeted biomarker analysis
• Immunophenotyping

The DMT 620M Wire Myograph™ system is used to conduct ex vivo vascular ring tension recording on multiple vessel types including the aorta, the pulmonary artery and the middle cerebral artery.  The highly sensitive, flexible system can accommodate vessels down to 100 μm in diameter.  Relaxation and contractile activity are measured using force transducers. The system:

• Allows ex vivo study of compound activity on vascular function
• Enables assessment of antagonist potency for receptor/agonist combinations in both naïve and diseased model tissues
• Assess vascular remodeling and function via pharmacologic challenge or evaluating length-tension relationships from therapeutic or prophylactic in vivo studies

Our experienced staff engage in a broad spectrum of studies, tissues, species, and disease states.

Scleroderma

Lupus

• Anti-GBM Serum Induced Nephritis in SVJ Mice
• AAV Induced Lupus Nephritis In Mice
• Systemic Lupus Erythematosus (SLE) in MRL/MpJ-Fas/J Mice
• Systemic Lupus Erythematosus (SLE) in NZBWF1/J Mice

Rheumatoid arthritis

• Collagen Induced Arthritis (CIA) In Rat
• Collagen Induced Arthritis In Mice (Mouse CIA)
• Antibody Induced Arthritis In Mouse (ManIA)
• Strep Cell Wall (SCW) Reactivation Arthritis (PGPS)
• Adjuvant Arthritis (AIA) In Rat
• Antigen Induced Knee Arthritis (Mouse)

Monoarticular inflammation/arthritis

• Inflammatory Bowel Disease
• MDR1a Spontaneous Colitis in Mice
• Adoptive T-Cell Transfer in Mice
• Anti-CD40 Colitis In Mice
• Dextran Sulfate Induced Colitis (DSS) in Mice
• Dextran Sulfate Salt Induced Colitis (DSS) in Rat
• Indomethacin Induced Crohn’s in Rats
• 2,4,6-Trinitrobenzenesulfonic acid (TNBS) Induced Colitis In Rats
• 2,4,6-Trinitrobenzenesulfonic acid (TNBS) Induced Colitis in Mice

• Osteoarthritis
• Partial Medial Meniscectomy-Induced Arthritis in Canine
• ACL Transection-Induced Arthritis in Walker Hound
• Medial Meniscal Tear-Induced OA (MMT) in Rats
• Monoiodoacetate-Induced Arthritis (MIA) in Rats
• Destabilization of the Medial Meniscus (DMM) in Rats & Mice
• Partial Lateral Meniscectomy Induced OA in Rabbits
• Spontaneous Osteoarthritis in Guinea Pigs
• Meniscal Tear-Induced Arthritis in Guinea Pigs

• Central Nervous System
• Glioblastoma Models in Mice
• Epilepsy Models in Rats and mice
• Addiction Models in Rats and Mice
• Cognition Models in Rats and Mice
• Experimental Autoimmune Encephalomyelitis (EAE)
• Developmental Milestones aka Functional Observation Battery
• Anxiety Models in Rats and Mice
• Depression Model in Rat
• Fragile X Syndrome (FXS) in Mice
• Parkinson’s Disease Models in Rats and Mice
• Alzheimer’s Disease Model in Mice

Myocardial infarction
Hypertension-based cardia dysfunction, hypertrophy, and failure
Cardiac hypertrophy, cardiac pressure overload, and heart failure

Left Ventricular Function, Cardiac remodeling and Histological evaluation
Methods: Echocardiography (M-Mode, B-Mode & Doppler), Pressure/Volume, Invastive LV Hemodynamics (+/-dP/dT, Tau, LVEDP and LVESP)
Disease Models: Myocardial Infarction, ZSF1, SHHF, Dahl Salt Sensitive (DSS) (additional models available)

Type 1 diabetes
Type 2 diabetes
Metabolism and diet

• Glucose and Insulin Tolerance Tests (OGTT/IPGTT)
• Fasting and fed blood glucose
• Cholesterol, HDL, LDL, Apolipoproteins, HbA1C, Microalbumin, Creatinine, etc.
• Adipose tissue and body weight
• Disease Models: Type I and II diabetes – ob/ob, db/db, DIO and STZ mice; ZDF and STZ rats (additional models available)

Hepatic fibrosis
Other hepatic conditions
Collagen/Hydroxyproline content
Serum ALT/AST/ALP
Portal Vein Pressure
Histological evaluation

Models: Carbon Tetrachloride (CCl4) and Bile Duct Ligation (BDL)

Pulmonary fibrosis
Pulmonary arterial hypertension
Acute lung injury
Airway hyper-responsiveness (AHR)/asthma
Right Ventricular Systolic Pressure/Pulmonary Arterial Pressure
Heart and Lung Weight
Myocardial, Pulmonary Artery and Lung Histology

Disease Models: Monocrotaline PAH

Acute kidney injury and failure (AKI/ARG)
Nephrotoxicity
Chronic kidney disease and renal insufficiency
Autoimmune kidney injury
Diabetic nephropathy
Proteinuria, albuminuria, GFR, Creatinine Clearance, histological evaluation
Plasma/Urine Biomarkers of damage
Chronic blood pressure monitoring using radio telemetry

Disease Models:: 5/6 Nephrectomy, Renal Ischemia/Reperfusion, Dahl Salt Sensitive (DSS), Streptozotocin (STZ), ZSF1, Unilateral Urethral Obstruction (UUO), Puromycin Aminonucleoside (PAN), Uninephrectomized (additional models available)

• Osteoarthritis
• Inflammatory
• Neuropathic
• Bone tumor

• Anemia
• Psoriasis
• Dermatitis
• Delayed type hyper-sensitivity
• Anaphylaxis
• Peritonitis
• Acute edema
• Pancreatitis

Non-GLP discovery toxicology
Regulated IND/CTA enabling

• Cardiovascular Safety
  • Cardiovascular Telemetry Platform – Continuous measurement of blood pressure, heart rate, ECG, respiration, temperature & activity in conscious, unrestrained animals for up to 6 months. Blood, urine, fecal and tissue sampling available.
  • Infusion Pharmacology Platform – Continuous infusion of test compound and simultaneous blood pressure & heart rate analysis for up to 14 days. Clinical observations, blood, urine, fecal and tissue sampling
  • Cardiac, Lipid and Metabolic Biomarkers – Markers of tissue and biochemical damage (e.g. CK, CRP, chol, trigs, glucose, HbA1c, etc.)
  • Echocardiography – Left Ventricular Function & Dimensions
  • Left Ventricular Function – +/-dP/dt, Tau, LVEDP and LVESP

• Renal Safety
  • Renal Function – Creatinine Clearance, GFR, proteinuria and electrolytes
  • Kidney Histology – Glomerulosclerosis, tubular damage, fibrosis, etc.
  • Renal Biomarker Panel – Analysis of FDA/EMA approved urinary biomarkers that are predictive of drug-induced renal toxicity and translatable to human nephrotoxicity

• General Safety and Toxicology (non-GLP)
  • Chronic Infusion Studies – Continuous infusion of test agent for up to 14 days. Clinical observations, blood, urine, fecal and tissue sampling
  • Hematology – 23-parameter complete blood count plus 5-point WBC differential analysis on blood samples from in-life studies
  • Clinical Chemistry – 180 analytes available including markers of liver, kidney, cardiac, pancreas and bone damage; as well as lipids, metabolic and inflammation
  • Histopathology – Standard or tailored to your target tissue of interest

• Gastrointestinal Safety and Function
  • Intestinal Motility – Charcoal meal test
  • Intestinal Secretion – Closed and Open loop models of fluid and electrolyte secretion as well as compound absorption

• Standard pharmacokinetic studies
• Pharmacokinetic, pharmacodynamic and metabolic sample collection
• Standard routes of administration: SC, PO, IP, IV, IA, IR, ID, ad libitum